What is Royalty Pharma's litifilimab — total commitments?

Royalty Pharma (RPRX) reported litifilimab — total commitments of $250.00M in Q1 2026.

What does litifilimab — total commitments mean?

The total amount of capital the company has agreed to invest in the Litifilimab program.

Products & Services · Total Commitments

Litifilimab — Total Commitments

Analysis

StatementSegment

CategoryCapital Allocation

SignalContext dependent

VolatilityStable

First reportedQ1 2026

Last reportedQ1 2026

Rolls up toTotal Commitments

How to read this metric

An increase indicates a larger capital allocation to the asset, while a decrease reflects the completion of funding obligations or a reduction in scope.

Detailed definition

This represents the aggregate contractual obligation of the firm to provide capital or funding for the development and c...

Peer comparison

Similar to total investment commitments or aggregate deal value in biopharma licensing and royalty acquisition agreements.

Metric ID: rprx_segment_litifilimab_total_commitments

Historical Data

1 periods

	Q1 '26
Value	$250.00M

Similar Metrics at Other Companies

BiogenBIIB View metric

Merck & Co.MRK View metric

The Travelers CompaniesTRV View metric

Merck & Co.MRK View metric

Vertex PharmaceuticalsVRTX View metric

LennarLEN View metric

Frequently Asked Questions

What is Royalty Pharma's litifilimab — total commitments?: Royalty Pharma (RPRX) reported litifilimab — total commitments of $250.00M in Q1 2026.
What does litifilimab — total commitments mean?: The total amount of capital the company has agreed to invest in the Litifilimab program.